专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL156360A USE OF PEPTIDES OR PROTEINS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THERAPEUTIC OR PREVENTIVE USE AGAINST INFLAMMATION 未知
公开(公告)号：IL156360A
公开(公告)日：2012-12-31
申请号：IL15636003
申请日：2003-06-09
申请人： FIBREX MEDICAL RES & DEV GMBH , PETZELBAUER PETER
发明人： PETZELBAUER PETER
IPC分类号： A61K38/17 , A61K38/00 , A61K38/36 , A61K39/00 , A61P7/02 , A61P9/10 , A61P29/00 , A61P37/00 , A61P37/06 , C07K5/078 , C07K5/083 , C07K5/097 , C07K5/103 , C07K5/117 , C07K7/00 , C07K14/00 , C07K14/75
摘要： Peptides or proteins (I), based on the alpha - and beta -chain sequences of fibrin/fibrinogen, or their salts, amides and/or mixtures with each other or other materials, have therapeutic and/or preventive use in human or veterinary medicine. Peptides or proteins of formula R 1R 2N-CH 2-C(O)-Z 1-Z 2 (I), or their salts, amides and/or mixtures with each other or other materials, have therapeutic and/or preventive use in human or veterinary medicine. R 1, R 2H or up to 10C saturated or unsaturated hydrocarbyl; Z 1histidine or proline residue; and Z 2arginine residue or a peptide or protein residue (preferably of 2-30 aminoacids) having an initial arginine residue. An independent claim is included for medicaments containing (I). ACTIVITY : Antiinflammatory; antibacterial; immunosuppressive; Antirheumatic; Antiarteriosclerotic; vasotropic; Thrombolytic; anticoagulant; cytostatic; antipsoriatic. In tests for inhibition of reperfusion damage after surgically induced ischemia in rat cardiac tissue, intravenous administration of Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg (Ia) at 800 Microg/kg reduced the precentage of dead tissue from 46% to 29%. MECHANISM OF ACTION : Fibrin antagonist; inhibition of fibrin-mediated adhesion of cells from the blood-stream onto vascular endothelium and/or migration of such cells into tissue; inhibition of deposition and adhesion of fibrin cleavage fragments on vascular walls.

2. 发明专利

AT414097B Treatment of shock, e.g. due to bacterial toxins or hemorrhagic shock associated with viral infections, comprises using peptides matching the inducible VE-cadherin binding moiety of human fibrin Bbeta-chain 未知
公开(公告)号：AT414097B
公开(公告)日：2006-09-15
申请号：AT10872004
申请日：2004-06-25
申请人： PETZELBAUER PETER DR , ZACHAROWSKI KAI DR
IPC分类号： A61K38/17 , A61K38/39
摘要： The use of peptides (I), which match the inducible VE-cadherin binding moiety of the Bbeta -chain of human fibrin (i.e. Bbeta 15-42), for the treatment of shock, is new, where (I) have a specific structure based on a glycyl-(histidyl or prolyl)-argininyl N-terminus and/or have a specific N-terminal sequence of 28 amino acids. The use of peptides (I), which match the inducible VE-cadherin binding moiety of the Bbeta -chain of human fibrin (i.e. Bbeta 15-42), is claimed for the production of a pharmaceutical preparation for the treatment of shock, where (I) are of formula R 1R 2N-CH 2-C(O)-Z 1-Z 2 (I') and/or have the N-terminal amino acid sequence Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg (I''). R 1, R 2H or saturated or unsaturated 1-10C (preferably 1-3C) hydrocarbyl; Z 1histidine or proline residue; Z 2arginine residue or a peptide or protein residue (preferably of 2-30 amino acids) with an initial arginine residue. ACTIVITY : Vasotropic; Antibacterial; Immunosuppressive; Virucide. In tests in mice with dengue viruses associated shock, the degree of mortality in a group treated with Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg (Ia) (Bbeta 15-42) at 4800 mu g/kg i.p. twice daily from day 3 to day 8 after infection was 0%, compared with 40% in an untreated control group. MECHANISM OF ACTION : Human fibrin Bbeta -chain inducible VE-cadherin binding moiety mimetic.

3. 发明专利

ATA10872004A 未知
公开(公告)号：ATA10872004A
公开(公告)日：2005-12-15
申请号：AT10872004
申请日：2004-06-25
申请人： PETZELBAUER PETER DR , ZACHAROWSKI KAI DR
IPC分类号： A61K38/17 , A61K38/39

4. 发明申请

WO2019011879A1 THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME 审中-公开
公开(公告)号：WO2019011879A1
公开(公告)日：2019-01-17
申请号：PCT/EP2018/068582
申请日：2018-07-09
申请人： HENNING, Rainer , WUELFROTH, Petra , ZACHAROWSKI, Kai , PETZELBAUER, Peter
发明人： HENNING, Rainer , WUELFROTH, Petra , ZACHAROWSKI, Kai , PETZELBAUER, Peter
IPC分类号： A61K38/16 , A61P9/00 , A61P35/00
CPC分类号： A61K38/16 , A61P9/00 , A61P35/00
摘要： The present invention relates to a method for inhibiting, treating and/or preventing a capillary leak syndrome in a subject treated with a T-cell or NK cell activating agent, said method comprising administering fibrin-derived peptide B Beta 15-42 and/or at least one derivative thereof or a physiologically acceptable salt thereof to said subject.

5. 发明申请

WO2010043444A3 BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY 审中-公开
公开(公告)号：WO2010043444A3
公开(公告)日：2010-04-22
申请号：PCT/EP2009/061342
申请日：2009-09-02
申请人： FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH , PETZELBAUER, Peter , HENNING, Rainer
发明人： PETZELBAUER, Peter , HENNING, Rainer
IPC分类号： A61K38/36 , A61K47/48 , C07K14/75 , A61K38/13 , A61K38/18 , A61K38/22 , A61K38/26 , A61K31/40 , A61K31/5025
摘要： The invention is concerned with a pharmaceutical composition consisting of two or more components, where at least one component binds to VE-cadherin and prevents capillary leak, tissue edema formation and acute inflammation and at least one other component activates the RISK pathway and/or prevents the opening of the mitochondrial permeability transition pore (MPTP).

6. 发明申请

WO2007095660A1 PEPTIDES AND PEPTIDE DERIVATIVES AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME 审中-公开
标题翻译：肽和肽衍生物作为含有其的药物组合物
公开(公告)号：WO2007095660A1
公开(公告)日：2007-08-30
申请号：PCT/AT2007/000095
申请日：2007-02-23
申请人： FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH , PETZELBAUER, Peter , HENNING, Rainer , REINGRUBER, Sonja
发明人： PETZELBAUER, Peter , HENNING, Rainer , REINGRUBER, Sonja
IPC分类号： C07K14/75 , A61K38/36
CPC分类号： C07K14/75 , A61K38/00 , Y02A50/385
摘要： Peptides and peptide derivatives of the following general Formula (I): H 2 N-GHRPX 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 PX 9 X 10 X 11 PX 12 PPPX 13 X 14 X 15 X 16 GYR-X 17 (I), wherein: X 1 -X 16 denote one of the 20 genetically encoded amino acids, X 17 denotes OR 1 , with R 1 = hydrogen or (C 1 -C 10 -alkyl), or NR 2 R 3 , R 2 and R 3 being identical or different and denoting hydrogen, (C 1 -C 10 )-alkyl, or a residue -PEG 5-60K , wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH-Y-Z-PEG 5-60K , wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof, or wherein: X 15 or X 16 denotes an amino acid from the group of C or K, which is linked to a residue Z-PEG 5-60K via the heteroatom in the side chain, and wherein X 17 denotes OR 1 , with R 1 = hydrogen or (C 1 -C 10 -alkyl), or NR 2 R 3 , R 2 and R 3 being identical or different and denoting hydrogen or (C 1 -C 10 )-alkyl, as well as the physiologically acceptable salts thereof.
摘要翻译：下列通式（I）的肽和肽衍生物：H 2 N-GHRPX 1 X 2 X 3 N / > X _{4 X _{5 X _{6 X _{7 X _{8 PX _{9 X _{10 X _{11 PX _{12 PPPX _{13 X _{14 X 15 X 16 GYR-X 17（I）其中：X 1 -X 16 表示20个遗传编码氨基酸之一，其中R 1 =氢或（C 1〜或者NR 2 R 3，R 2，R 2，R 3，R 3，R 3，和R 3相同或不同，表示氢，（C 1 -C 10 - ） - 烷基或残基-PEG < 5-60K，其中PEG残基通过间隔基连接到N原子，或残基NH-YZ-PEG 5-60K，其中Y表示化学键或来自S，C，K或R组的遗传编码氨基酸，Z表示间隔基，通过其可以使用聚乙二醇（PEG）可以连接残基，以及其生理上可接受的盐，或其中：X 15或X 16表示C或K基团的氨基酸，其中通过侧链中的杂原子与残基Z-PEG 5-60K连接，其中X 17表示OR 1，其中R 或者是C 1 -C 12烷基，或NR 2 R 3 R 2，R 3和R 3相同或不同，表示氢或（C 1 -C 10 - SUB - ） - 烷基，以及其生理上可接受的盐。}}}}}}}}}}}

7. 发明申请

WO2010043444A2 PHARMACEUTICAL PREPARATION FOR THE TREATMENT AND/OR PREVENTION OF ISCHEMIA/REPERFUSION INJURY AND THE SEQUELS THEREOF 审中-公开
标题翻译：用于治疗和/或预防隔离/再灌注损伤的药物制剂及其序列
公开(公告)号：WO2010043444A2
公开(公告)日：2010-04-22
申请号：PCT/EP2009061342
申请日：2009-09-02
申请人： FIBREX MEDICAL RES & DEV GMBH , PETZELBAUER PETER , HENNING RAINER
发明人： PETZELBAUER PETER , HENNING RAINER
IPC分类号： A61K47/48 , A61K31/5025 , A61K38/13 , A61K38/36 , A61P9/10 , C07K14/75
CPC分类号： A61K38/2242 , A61K31/00 , A61K31/40 , A61K31/5025 , A61K38/13 , A61K38/1816 , A61K38/26 , A61K38/363 , A61K45/06 , A61K47/60 , C07K14/75 , A61K2300/00
摘要： The invention is concerned with a pharmaceutical composition consisting of two or more components, where at least one component binds to VE-cadherin and prevents capillary leak, tissue edema formation and acute inflammation and at least one other component activates the RISK pathway and/or prevents the opening of the mitochondrial permeability transition pore (MPTP).
摘要翻译：本发明涉及由两种或更多种组分组成的药物组合物，其中至少一种组分与VE-钙粘蛋白结合并防止毛细血管渗漏，组织水肿形成和急性炎症，并且至少一种其它组分激活RISK途径和/或预防线粒体通透性转换孔（MPTP）的开放。

8. 发明申请

WO2009137852A1 PEPTIDES AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：其制备方法及其衍生物，其制备方法及其用于制备治疗性和/或预防性活性药物组合物的用途
公开(公告)号：WO2009137852A1
公开(公告)日：2009-11-19
申请号：PCT/AT2009/000160
申请日：2009-04-21
申请人： FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH , PETZELBAUER, Peter , REINGRUBER, Sonja , PASTEINER, Waltraud , HENNING, Rainer
发明人： PETZELBAUER, Peter , REINGRUBER, Sonja , PASTEINER, Waltraud , HENNING, Rainer
IPC分类号： C07K14/75 , A61K38/36
CPC分类号： C07K14/75 , A61K38/00
摘要： Peptides and derivatives thereof of the following general formula (I): H 2 N-GHRPX 1 X 2 PX 3 X 4 X 5 PX 6 PPPX 7 X 8 X 9 X 10 B(1)B(2)B(3)-X 11 , wherein: B(1) denotes either a chemical bond or the amino acid G; B(2) denotes either a chemical bond or the amino acid Y; B(3) denotes either a chemical bond or the amino acid R. X 1 - X 10 denote one of the 20 genetically encoded amino acids, X 11 denotes OR 1 with R 1 = hydrogen or (C 1 -C 10 -alkyl), or NR 2 R 3 , R 2 and R 3 being identical or different and denoting hydrogen, (C 1 -C 10 )-alkyl, or a residue -PEG 5-60K , wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH-Y-Z-PEG 5-60K , wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof.
摘要翻译：下列通式（I）的肽及其衍生物：H2N-GHRPX1X2PX3X4X5PX6PPPX7X8X9X10B（1）B（2）B（3）-X11，其中：B（1）表示化学键或氨基酸G; B（2）表示化学键或氨基酸Y; B（3）表示化学键或氨基酸R. X1-X10表示20个遗传编码氨基酸之一，X11表示OR1，R1 =氢或（C1-C10-烷基）或NR2R3，R2和R3 相同或不同，表示氢，（C1-C10） - 烷基或残基-PEG5-60K，其中PEG残基通过间隔基或残基NH-YZ-PEG5-60K与N原子连接，其中Y表示S，C，K或R组中的化学键或遗传编码氨基酸，Z表示可以连接聚乙二醇（PEG）残基的间隔基，以及其生理上可接受的盐。

9. 发明申请

WO2009039542A9 METHODS OF SCREENING FOR COMPOUNDS HAVING ANTI-INFLAMMATORY ACTIVITY 审中-公开
标题翻译：筛选具有抗炎活性的化合物的方法
公开(公告)号：WO2009039542A9
公开(公告)日：2009-05-14
申请号：PCT/AT2008000337
申请日：2008-09-22
申请人： FIBREX MEDICAL RES & DEV GMBH , PETZELBAUER PETER , HENNING RAINER , REINGRUBER SONJA , PASTEINER WALTRAUD , GROEGER MARION
发明人： PETZELBAUER PETER , HENNING RAINER , REINGRUBER SONJA , PASTEINER WALTRAUD , GROEGER MARION
IPC分类号： G01N33/50 , C12Q1/42 , C12Q1/48 , G01N33/543 , G01N33/58
CPC分类号： G01N33/5064 , C12Q1/42 , C12Q1/485 , G01N33/5088 , G01N33/54313 , G01N33/582 , G01N33/585 , G01N2500/00 , G01N2800/065 , G01N2800/067 , G01N2800/085 , G01N2800/122 , G01N2800/125 , G01N2800/164 , G01N2800/202 , G01N2800/205 , G01N2800/224 , G01N2800/24 , G01N2800/245 , G01N2800/26 , G01N2800/324 , G01N2800/328 , G01N2800/347
摘要： A method of screening for compounds out of the group consisting of proteins, peptides, peptidomimetics, antibodies or small organic molecules that increase the activity of the protein Rac1 by virtue of their binding to the extracellular portion of this protein, the method comprising the steps of: a) contacting a confluent layer of cultured endothelial cells grown on porous membranes with at least one of the test compounds alone or together with a stimulant of vascular permeability, b) measuring the endothelial permeability with a suitable agent, which can be colorimetrically detected.
摘要翻译：筛选由蛋白质，肽，肽模拟物，抗体或小有机分子组成的组中的化合物的方法，其通过与蛋白质的细胞外部分结合而增加蛋白质Rac1的活性，所述方法包括以下步骤： a）使生长在多孔膜上的培养的内皮细胞的融合层与单独的至少一种测试化合物或血管渗透性的兴奋剂一起接触，b）用可以比色测定的合适试剂测量内皮渗透性。

10. 发明申请

WO2007070899A2 PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON HÄMORRHAGISCHEM SCHOCK UND SEINEN FOLGEERSCHEINUNGEN 审中-公开
标题翻译：用于治疗出血性休克的药物组合物及其后果
公开(公告)号：WO2007070899A2
公开(公告)日：2007-06-28
申请号：PCT/AT2006/000465
申请日：2006-11-10
申请人： FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH , PETZELBAUER, Peter , HENNING, Rainer
发明人： PETZELBAUER, Peter , HENNING, Rainer
IPC分类号： A61K38/36 , A61P7/04
CPC分类号： A61K38/16 , Y02A50/411
摘要： Die Erfindung betrifft die Verwendung eines Peptids, umfassend die N-terminale Sequenz Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala- Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg oder irgendeiner allelen Variante oder Derivats dieses Peptids, welche bzw. welches die biologische Eigenschaft besitzt, mit dem induzierbaren VE-Cadherin-Bindungsmotiv an der Bβ-Kette (d.h. Bβ 15-42 ) des menschlichen Fibrins zusammenzupassen, für die Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Schock, genauer gesagt eines hämorrhagischen Schocks.
摘要翻译：
本发明涉及使用包含N末端序列Gly-His的基-Arg-Pro-LEU-ASP-赖氨酸 - 赖氨酸 - 精氨酸 - GLU-GLU-丙氨酸 - 脯氨酸 - 丝氨酸的肽的亮氨酸 - 精氨酸 - 脯氨酸 - 丙氨酸 - 脯氨酸 - 脯氨酸 - 脯氨酸 - 异亮氨酸 - 丝氨酸 - 甘氨酸 - 甘氨酸 - 甘氨酸 - 酪氨酸 - 精氨酸或该肽的任何等位变体或衍生物，其中的任一个具有相匹配的可诱导的生物学特性VE 在B.beta链钙粘蛋白结合基序（即B.beta <子> 15-42 ）一起人纤维蛋白，F导航的使用，具体地，用于治疗休克的药物组合物的制备准确地R A手中。失血性休克

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式